Elzbieta Zlowocka-Perlowska
Overview
Explore the profile of Elzbieta Zlowocka-Perlowska including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
433
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Blood and Serum Se and Zn Levels and 10-Year Survival of Patients after a Diagnosis of Kidney Cancer
Zlowocka-Perlowska E, Baszuk P, Marciniak W, Derkacz R, Toloczko-Grabarek A, Slojewski M, et al.
Biomedicines
. 2024 Aug;
12(8).
PMID: 39200240
The aim of the project was to evaluate the association between selenium (Se) and zinc (Zn) levels in blood and serum and kidney cancer mortality. In a prospective group of...
2.
Zlowocka-Perlowska E, van de Wetering T, Toloczko-Grabarek A, Scott R, Lubinski J
Oncotarget
. 2022 Apr;
13:628-640.
PMID: 35478773
Purpose: The association between the c.3020insC allele and missense variant c.442G>A (p.P.A148T) and survival of patients with bladder or kidney cancer remains controversial. Materials And Methods: We compared the allele...
3.
Zlowocka-Perlowska E, Toloczko-Grabarek A, Narod S, Lubinski J
Hered Cancer Clin Pract
. 2022 Apr;
20(1):13.
PMID: 35395863
Introduction: The role of the BRCA1 and BRCA2 genes in bladder and renal tumorigenesis is unclear. Our goal was to determine the prevalence of specific founder mutations genes BRCA1 (5328...
4.
Zlowocka-Perlowska E, Toloczko-Grabarek A, Lubinski J
Hered Cancer Clin Pract
. 2022 Jan;
20(1):1.
PMID: 34983599
Introduction: The role of HOXB13 in bladder and renal tumorigenesis is unclear. Our goal was to determine the prevalence of HOXB13 p.G84E mutation in bladder and kidney cancer patients from...
5.
Zlowocka-Perlowska E, Debniak T, Slojewski M, van de Wetering T, Toloczko-Grabarek A, Cybulski C, et al.
PLoS One
. 2021 Sep;
16(9):e0257132.
PMID: 34499690
Purpose: The purpose of this study was to compare the clinical characteristics and the survival of CHEK2 mutation positive and CHEK2 mutation negative patients diagnosed with bladder or kidney cancer....
6.
Zlowocka-Perlowska E, Debniak T, Slojewski M, Leminski A, Soczawa M, van de Wetering T, et al.
Hered Cancer Clin Pract
. 2021 Jan;
19(1):6.
PMID: 33419454
Introduction: The role of PALB2 in carcinogenesis remains to be clarified. Our main goal was to determine the prevalence of PALB2 (509_510delGA and 172_175delTTGT) mutations in bladder and kidney cancer...
7.
Zlowocka-Perlowska E, Narod S, Cybulski C
JAMA Oncol
. 2019 Mar;
5(4):576.
PMID: 30816943
No abstract available.
8.
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer
Rebbeck T, Mitra N, Wan F, Healey S, McGuffog L, Chenevix-Trench G, et al.
JAMA
. 2015 Apr;
313(13):1347-61.
PMID: 25849179
Importance: Limited information about the relationship between specific mutations in BRCA1 or BRCA2 (BRCA1/2) and cancer risk exists. Objective: To identify mutation-specific cancer risks for carriers of BRCA1/2. Design, Setting,...
9.
Couch F, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker K, et al.
PLoS Genet
. 2013 Apr;
9(3):e1003212.
PMID: 23544013
BRCA1-associated breast and ovarian cancer risks can be modified by common genetic variants. To identify further cancer risk-modifying loci, we performed a multi-stage GWAS of 11,705 BRCA1 carriers (of whom...
10.
Lener M, Jaworska K, Muszynska M, Sukiennicki G, Durda K, Gupta S, et al.
Pol Przegl Chir
. 2012 Dec;
84(9):470-5.
PMID: 23241574
No abstract available.